The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly
NCT ID: NCT06658821
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
100 participants
INTERVENTIONAL
2025-02-27
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients
NCT03005873
Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee
NCT02803307
Therapeutic Effect of Oral Hyaluronic Acid on Knee Osteoarthritis
NCT07033312
The Role of Synovitis in Osteoarthritis
NCT03167333
A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis
NCT05807529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LDL557-HK capsule
Subjects will take one capsule of the experimental group(LDL557-HK capsule) within 30 minutes before lunch during the experimental period.
LDL557-HK capsule
Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
Placebo capsule
Subjects will take one placebo capsule within 30 minutes before lunch during the experimental period.
Placebo Capsule
Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LDL557-HK capsule
Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
Placebo Capsule
Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those with early stage degenerative arthritis symptoms judged by X-ray to be Kellgren-Lawrence Grading Scale level 1 or 2, and the physician determines that long-term treatment is not needed or WOMAC score\>2.0 or WOMAC total scale score\>12 or VAS score ≦6.
Exclusion Criteria
* alcoholism
* diabetes
* breastfeeding women and pregnant women.
* Those consuming dietary supplements were excluded.
* Those who use non-steroidal anti-inflammatory analgesics and those who have had joint surgery.
* Rheumatoid arthritis.
* Those who have had joint injections within 6 months.
* Those with cardiovascular and cerebrovascular, rheumatoid or mental diseases.
* Patients undergoing cancer treatment.
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SYNBIO TECH INC. Kaohsiung Taiwan
UNKNOWN
Chung Shan Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chung Shan Medical University
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS2-24147
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.